Last updated: February 26, 2026
What is the drug associated with NDC 70000-0580?
The NDC 70000-0580 corresponds to Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a triple monoclonal antibody combination developed by Regeneron Pharmaceuticals. It is approved for treatment of Ebola virus disease in adults and pediatric patients.
Market landscape for Ebola treatment drugs
Current approved treatments
| Drug Name |
Type |
Approval Date |
Market Authorization |
Indications |
| Inmazeb |
Monoclonal antibody combo |
Dec 2020 |
FDA, EMA, WHO |
Ebola virus disease |
| Ebanga (mAb114) |
Monoclonal antibody |
Dec 2020 |
FDA, EMA |
Ebola virus disease |
Market size estimates
- Washington-based GlobalData estimates the 2022 global Ebola treatment market at approximately $550 million with forecast growth, largely driven by outbreaks in Central and West Africa.
- The number of cases fluctuates yearly, with recent outbreaks in the Democratic Republic of Congo (DRC), Guinea, and Uganda.
Key market drivers
- Outbreak frequency: Ebola's unpredictable outbreaks compel stockpiling and fast deployment.
- Regulatory support: Emergency use authorizations and WHO prequalification accelerate uptake.
- Competition: Limited, primarily Monoclonal antibody therapies; no vaccines are used as therapeutics.
Price analysis
Current pricing strategies
| Product |
Price per dose |
Dosing regimen |
Cost considerations |
| Inmazeb |
Approximately $50,000 |
Single dose, IV infusion |
High cost linked to complex manufacturing and emergency supply characteristics |
| Ebanga |
Approximately $35,000 |
Single dose, IV infusion |
Slightly lower due to manufacturing efficiencies |
Note: Prices are approximations based on publicly available data and industry sources (Statista, 2022). Actual pricing may vary per healthcare system and procurement agreements.
Price projections
-
Short-term (2023–2025): Expect maintenance of current prices amid supply constraints and limited competition.
-
Medium-term (2025–2030): Possible price reduction to between $30,000 and $40,000 per dose, driven by increased manufacturing capacity, potential biosimilars, and negotiations with global procurement agencies.
-
Long-term (beyond 2030): Price stabilization and potential decline if generic or biosimilar versions enter the market, with prices potentially dropping below $20,000 per dose.
Factors influencing future prices
- Increased manufacturing capacity through new facilities and technology.
- Competition from emerging monoclonal antibody products.
- International procurement negotiations and batch purchasing at the WHO level.
- Regulatory advances streamlining approval for biosimilars.
Market outlook considerations
- The demand for Ebola therapeutics remains heavily contingent on outbreak dynamics.
- Broader global health initiatives could expand access, especially in low-income settings.
- Emerging therapies, such as antiviral drugs and vaccines, may impact the market share of monoclonal antibodies over time.
Regulatory and policy factors
- WHO prequalification and emergency use listings influence procurement.
- Price negotiations with agencies like USAID, GAVI, and the Global Fund affect market penetration.
- Potential for global stockpiles to influence pricing and distribution.
Key Trends
- Increasing pressure to lower prices due to aid budgets.
- Expansion of manufacturing capacity to meet sporadic demand.
- Rising interest in biosimilars to reduce overall treatment costs.
Final summary
NDC 70000-0580, associated with Inmazeb, commands high prices driven by complex manufacturing, emergency needs, and limited competition. Prices remain stable short-term due to the pandemic response and outbreak unpredictability. Medium to long-term, prices are projected to decline as manufacturing scales and biosimilar options emerge.
Key Takeaways
- The current per-dose price for NDC 70000-0580 is approximately $50,000.
- Market size remains limited but vital due to Ebola's outbreak potential.
- Price reductions are anticipated over the next five to ten years, influenced by increased manufacturing capacity and biosimilar development.
- Supply and demand fluctuations significantly impact procurement costs.
- Policy negotiations and international health initiatives are crucial to future pricing and access.
FAQs
1. What factors primarily influence the price of NDC 70000-0580?
Manufacturing complexity, supply demand dynamics during outbreaks, regulatory negotiations, and competition from emerging products.
2. How does the current Ebola outbreak landscape affect market demand?
Fluctuating outbreaks drive unpredictable demand; large-scale outbreaks lead to increased ordering and stockpiling.
3. What is the outlook for biosimilar versions of Inmazeb?
Potential biosimilars could enter the market within five to ten years, potentially decreasing prices significantly.
4. Are there any price caps or regulations impacting Ebola treatment drugs?
Funding agencies and international organizations influence prices through procurement negotiations; no explicit global caps exist.
5. How do supply chain issues impact the market?
Manufacturing bottlenecks and distribution challenges during outbreaks affect availability and pricing stability.
References
[1] Statista. (2022). Global Ebola treatment market size and forecasts.
[2] U.S. Food and Drug Administration (FDA). (2020). FDA approval of Inmazeb.
[3] World Health Organization. (2021). Ebola virus disease: current outbreaks and response.
